Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
March 20 2023 - 4:01PM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage
biopharmaceutical developing a novel therapeutic that targets toxic
soluble amyloid beta oligomers for the treatment of Alzheimer’s
disease, today announced that the Company will report fourth
quarter and year-end 2022 financial results on Monday, March 27,
2023. The Company will host a conference call and live audio
webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register
using this link. After registration, you will be informed of the
dial-in numbers including PIN. Please register at least one day in
advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at
least 30 days in the Investors section of the Company's website at
www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA,
with clinical operations based in Carmel, IN, is a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers (AβOs) for the
treatment of Alzheimer’s disease (AD). Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are primary triggers of Alzheimer’s disease pathology.
Acumen is currently focused on advancing its investigational
product candidate, ACU193, a humanized monoclonal antibody that
selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1
clinical trial involving early Alzheimer’s disease patients. For
more information, visit www.acumenpharm.com.
Investors: Alex Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Jul 2023 to Jul 2024